A Phase 1 interventional study of Eptinezumab in Migraine in Children and Migraine, sponsored by H. Lundbeck A/S. Completed at 9 sites in United States. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2023-10-06.
Sponsored by H. Lundbeck A/S · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing eptinezumab in Migraine Disorders — 6 open to participants now, 6 under way, 5 of them phase 3. eptinezumab · Migraine Disorders.
Among the 21 studies testing eptinezumab in Migraine Disorders, this one is the 21st largest by enrollment, is one of 2 that started in 2020, is one of 3 in phase 1, and was the 9th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.
Browse Migraine Disorders studies →6 of the 21 studies testing eptinezumab in Migraine Disorders are open now, in 11 countries. Recruiting first, the newest first:
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18–65
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 6–17
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 6–17
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 12–17
Dr George Medvedev · Sites in Canada
Ages 19–75
By country, each count listing its studies:
eptinezumab: first FDA approval 2020 (VYEPTI), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 193 across the 21 interventional studies. Of the 15 that completed or were terminated, 8 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 21 have an industry lead sponsor. The 5 most frequent:
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
23 studies in Migraine Disorders by H. Lundbeck A/S: 3 open now, 3 under way, 3 of them phase 3. Of 20 finished, 9 (45%) have results posted.
Among the 23 studies in Migraine Disorders by H. Lundbeck A/S, this one is the 23rd largest by enrollment, is one of 2 that started in 2020, is one of 6 in phase 1, and was the 10th registered.
H. Lundbeck A/S’s Migraine Disorders studies by the year they started, since 2012.
3 of the studies testing eptinezumab in Migraine Disorders that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04965675Phase 3H. Lundbeck A/SA Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine | 2027-03-26 |
| NCT07191145Phase 3Sunnybrook Health Sciences CentreEary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT) | 2027-06-30 |
| NCT05897320Phase 3H. Lundbeck A/SA Study of Eptinezumab in Pediatric Participants With Episodic Migraine | 2027-07-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies testing eptinezumab in Migraine Disorders, from their registry updates:
Among H. Lundbeck A/S’s 23 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to investigate how the body absorbs, distributes, and get rid of eptinezumab when given directly into a vein.
This is an interventional, open-label pharmacokinetic study with eptinezumab, consisting of a single-dose, 20-week main study period (Part A) and an optional 44-week multiple-dose extension period (Part B).
The main study period includes a single IV infusion of eptinezumab. The optional extension period includes 3 additional eptinezumab infusions 12 weeks apart (reflecting recommended dosing interval in adults), for a total of up to 4 infusions over the course of the study.
At least 32 patients with migraine will be enrolled: 16 patients aged 6 to 11 years, and 16 patients aged 12 to 17 years, inclusive.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other in- and exclusion criteria may apply
Drug: Eptinezumab
up to four iv infusions of eptinezumab
Area under curve (AUC) (0-infinity) eptinezumab
Area under the plasma concentration curve for eptinezumab from zero to infinity
Time frame: From dosing to week 20
Cmax eptinezumab
Maximum observed plasma concentration of eptinezumab
Time frame: From dosing to week 20
Clearance (CL)
Plasma clearance
Time frame: From dosing to week 20
Volume of distribution (Vz)
Time frame: From dosing to week 20
Development of anti-eptinezumab antibodies (ADA)
Time frame: From screening to week 12
Characterization of anti-eptinezumab antibodies for neutralizing activity (NAb)
Time frame: From screening to week 12
Ran from Aug 2020 to primary completion in Oct 2022, 26 months.
Of 39 industry-sponsored phase 1 interventional studies under Migraine Disorders, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's 26 months is above that.
Counting every sponsor, half of 53 studies reached it within 6 months; a quarter within 2 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eptinezumab